# An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

> **NCT01381809** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 130 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Group 2: Placebo
- **DRUG:** Group 1: Epoetin alfa

## Key facts

- **NCT ID:** NCT01381809
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-01
- **Final completion:** 2016-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381809, "An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01381809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*